Anrotinib is a small molecule multi-target tyrosine kinase inhibitor that effectively inhibits VEGFR, PDGFR, FGFR, c-Kit and other kinases. It is indicated as a single agent for patients with progressive or recurrent locally advanced or metastatic non-small cell lung cancer after receiving at least two prior systemic chemotherapies. For patients with mutations in the epidermal growth factor receptor gene, or who are kinase positive for mesenchymal lymphoma, treatment with the appropriate targeted agent should be initiated prior to starting treatment with this product. According to the latest treatment principle of tumor-targeted drugs in the United States, i.e. treating the same disease and treating different diseases, it is recommended that all tumor drugs should obtain pathological genetic testing before use. If there are mutations in VEGFR, FGFR, PDGFR, c-Kit, etc., the use of Anrotinib should be effective. Currently, Anrotinib is used internationally as the only drug of choice for sarcoma, i.e. very effective, so good results are achieved in the clinic. When the sarcoma is very big, it basically shrinks more than 50% with Anrotinib for about one week. It also has good effect in liver cancer as well as some ovarian cancer, breast cancer, biliary tumor, esophageal cancer, head and neck tumor, which is the landmark drug of domestic targeted drug.